Asian Fund for Cancer Research Limited Unveils Inspiring New Logo and Slogan, signifying a Global Commitment to Advancing Cancer Research – from Asia to the World.

The Asian Fund for Cancer Research (AFCR) is thrilled to unveil its fresh brand logo and slogan, marking a pivotal moment in the organization’s quest to advance breakthroughs in cancer globally. The redesigned emblem and impactful slogan firmly establish AFCR as a prominent voice in the ongoing battle against cancer, extending its influence beyond Asia.

“Advancing Cancer Breakthroughs from Asia to the World”: This compelling slogan powerfully encapsulates AFCR’s unwavering commitment to drive innovation and foster collaboration in cancer research with a global impact. Accentuating the translation of discoveries from the vibrant laboratories of Asia to positively influence patients worldwide, the slogan illuminates AFCR’s pivotal role in spearheading the international fight against cancer.

AFCR is acutely aware of the critical necessity to confront Asian-specific cancers—such as hepatocellular carcinoma (HCC), lung cancer, gastrointestinal (GI) cancer, esophageal cancer, and ovarian cancer. These unique challenges necessitate targeted research initiatives, and AFCR stands devoted to championing groundbreaking research projects, precisely tailored to these cancers. The AFCR mission extends beyond borders, aiming not only to enhance treatment modalities and improve early detection methods but also to establish collaborative networks that seamlessly facilitate knowledge sharing among researchers on a global scale.

Dr. Sujuan Ba, Founder, President & CEO of AFCR, expressed her excitement about the new logo and slogan, affirming, “Our revamped visual identity, coupled with the powerful slogan, signifies a significant stride in our dedication to propelling cancer research on a global scale. It reinforces our mission to connect Asian research initiatives with the worldwide effort against cancer.”

As an example of the impact AFCR can provide to the cancer research community, in support of improved care for patients, AFCR is championing an innovative immunotherapy for gastrointestinal (GI) cancer, addressing a significant unmet clinical need. Leveraging the success of immunotherapy in certain cancers, AFCR supports a groundbreaking multi-targeting immunotherapeutic platform. This approach centers on the biomarker CDH17, highly expressed in 50-95% of GI cancers, making it an excellent target. The platform includes bi-specific antibodies that target both CDH17 and the CD3 marker on T cells, redirecting T cells to exert their cell-killing function on tumor cells. This novel immunotherapy offers a safer and more targeted solution for GI cancer patients, presenting a real breakthrough where no effective treatment existed before.Given the pressing health crisis posed by GI cancers globally, particularly in Asia, The program could offer potential safe and effective treatment for GI cancer where none was available previously.  with the potential to save millions of lives worldwide.

AFCR’s fresh brand logo is a catalyst for expanding engagement and diversifying support, strategically positioning the organization to propel its mission forward. As we look ahead, AFCR, with optimism and determination, anticipates exciting collaborations, groundbreaking discoveries, and a growing community committed to the fight against cancer. The logo not only reflects the organization’s dedication but also points at a future where AFCR’s impact resonates even more profoundly in the global battle against cancer.


About the Asian Fund for Cancer Research

The Asian Fund for Cancer Research (AFCR) is a nonprofit organization committed to combatting cancers that disproportionately affect Asian populations. Headquartered in Hong Kong and with a global reach, AFCR is uniquely positioned to investigate the unique causes of cancer in Asian demographics through innovative genetic and molecular research. The organization accelerates cutting-edge cancer research breakthroughs and technologies while developing more potent therapies for cancer patients across Asia and the world. Further insights can be found at